In recent years, a few reports have also conducted meta-analyses of available studies on correlations between LOXL2 overexpression and clinicopathological behaviour in tumours, primarily focusing on digestive system tumours and a few other types, such as oesophageal squamous cell carcinoma, breast cancer, and non-small-cell lung cancer [31]. The gene discussed is LOXL2; the disease is breast cancer.